Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19.

Szczegóły
Abstrakt

Tytuł:: Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19.
Autorzy:: Naci H; Department of Health Policy, London School of Economics and Political Science, London, UK .
Kesselheim AS; Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Røttingen JA; Research Council of Norway, Oslo, Norway.; Blavatnik School of Government, University of Oxford, Oxford, UK.
Salanti G; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Vandvik PO; Department of Health Management and Health Economics, University of Oslo, Oslo, Norway.
Cipriani A; Department of Psychiatry, University of Oxford, Oxford, UK.; Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK.
Źródło:: BMJ (Clinical research ed.) [BMJ] 2020 Oct 16; Vol. 371, pp. m3869. Date of Electronic Publication: 2020 Oct 16.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: London : British Medical Association
MeSH Terms:: Coronavirus Infections*/drug therapy
Coronavirus Infections*/epidemiology
Coronavirus Infections*/therapy
Drug Development*/organization & administration
Drug Development*/trends
Evidence-Based Medicine*/ethics
Evidence-Based Medicine*/methods
Evidence-Based Medicine*/trends
Pandemics*
Pneumonia, Viral*/epidemiology
Pneumonia, Viral*/therapy
Quality Improvement*
Betacoronavirus ; COVID-19 ; Comparative Effectiveness Research ; Ethics, Research ; Humans ; International Cooperation ; Randomized Controlled Trials as Topic/methods ; Randomized Controlled Trials as Topic/standards ; Research Design/standards ; SARS-CoV-2 ; Translational Research, Biomedical ; COVID-19 Drug Treatment
Entry Date(s):: Date Created: 20201017 Date Completed: 20201026 Latest Revision: 20221207
Update Code:: 20240105
DOI:: 10.1136/bmj.m3869
PMID:: 33067179
: Czasopismo naukowe

Competing Interests: Competing interests: POV is co-founder and chief executive of the non-profit MAGIC Evidence Ecosystem Foundation (www.magicevidence.org) and receives a fixed part time salary for his work. AC has received research and consultancy fees from INCiPiT (Italian Network for Paediatric Trials), Cariplo Foundation, and Angelini Pharma.

Informacja